logo
Is It Time To Consider Buying SGH Limited (ASX:SGH)?

Is It Time To Consider Buying SGH Limited (ASX:SGH)?

Yahoo27-03-2025

Today we're going to take a look at the well-established SGH Limited (ASX:SGH). The company's stock saw a decent share price growth of 14% on the ASX over the last few months. The company is inching closer to its yearly highs following the recent share price climb. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. However, what if the stock is still a bargain? Let's examine SGH's valuation and outlook in more detail to determine if there's still a bargain opportunity.
The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
According to our valuation model, the stock is currently overvalued by about 27%, trading at AU$51.15 compared to our intrinsic value of A$40.32. Not the best news for investors looking to buy! If you like the stock, you may want to keep an eye out for a potential price decline in the future. Given that SGH's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.
See our latest analysis for SGH
Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 53% over the next couple of years, the future seems bright for SGH. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.
Are you a shareholder? It seems like the market has well and truly priced in SGH's positive outlook, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe SGH should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.
Are you a potential investor? If you've been keeping tabs on SGH for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there's no upside from mispricing. However, the positive outlook is encouraging for SGH, which means it's worth diving deeper into other factors in order to take advantage of the next price drop.
So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. At Simply Wall St, we found 1 warning sign for SGH and we think they deserve your attention.
If you are no longer interested in SGH, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Yahoo

timean hour ago

  • Yahoo

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

American Rare Earths Leads ASX Penny Stocks To Consider
American Rare Earths Leads ASX Penny Stocks To Consider

Yahoo

time3 hours ago

  • Yahoo

American Rare Earths Leads ASX Penny Stocks To Consider

As the Australian market experiences a gradual decline, influenced by profit-taking and external geopolitical tensions, investors are seeking opportunities beyond traditional large-cap stocks. Penny stocks, though an older term, continue to attract attention for their potential to offer surprising value and growth at lower price points. By focusing on companies with strong balance sheets and solid fundamentals, investors may uncover hidden gems that provide upside without many of the risks typically associated with this segment of the market. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$70.76M ★★★★★★ GTN (ASX:GTN) A$0.65 A$124.05M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$725.72M ★★★★★☆ Regal Partners (ASX:RPL) A$2.25 A$756.37M ★★★★★★ Accent Group (ASX:AX1) A$1.845 A$1.11B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.37 A$159.91M ★★★★★★ CTI Logistics (ASX:CLX) A$1.815 A$146.19M ★★★★☆☆ Click here to see the full list of 1,001 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: American Rare Earths Limited focuses on the exploration and development of mineral resources in Australia and the United States, with a market cap of A$139.54 million. Operations: American Rare Earths Limited currently does not report any revenue segments. Market Cap: A$139.54M American Rare Earths Limited, with a market cap of A$139.54 million, is pre-revenue and debt-free, focusing on the exploration of mineral resources in Australia and the U.S. Recent developments include significant progress at their Cowboy State Mine in Wyoming, where groundwater monitoring wells have been installed as part of environmental permitting efforts. The company also reported promising assay results from its Halleck Creek project, highlighting elevated rare earth mineralization. Leadership changes have strengthened its executive team with seasoned professionals to advance its U.S.-based strategy for developing a secure critical minerals supply chain. Click here to discover the nuances of American Rare Earths with our detailed analytical financial health report. Learn about American Rare Earths' historical performance here. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Horizon Gold Limited is involved in the exploration, evaluation, development, and production of gold deposits in Australia with a market cap of A$86.90 million. Operations: The company's revenue segment consists of A$0.08 million from exploration activities in Australia. Market Cap: A$86.9M Horizon Gold Limited, with a market cap of A$86.90 million, is pre-revenue and debt-free, focusing on gold exploration in Australia. The company recently reported a small net income for the half-year ended December 31, 2024, marking an improvement from the previous year's loss. Its management team is experienced with an average tenure of 4.5 years and has seen leadership changes to bolster corporate development efforts as it progresses through the Gum Creek Feasibility Study. While its short-term assets cover liabilities, long-term liabilities remain uncovered by current assets. Shareholder dilution has been minimal over the past year. Unlock comprehensive insights into our analysis of Horizon Gold stock in this financial health report. Gain insights into Horizon Gold's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Ltd is an online retailer based in Australia with a market capitalization of A$401.23 million. Operations: The company's revenue is derived from its operations in Australia, with A$309.36 million from Kogan Parent and A$9.96 million from Mighty Ape, as well as in New Zealand, where it generates A$40.02 million from Kogan Parent and A$124.88 million from Mighty Ape. Market Cap: A$401.23M with a market cap of A$401.23 million, is debt-free and has extended its buyback plan duration until May 2026. Despite stable weekly volatility over the past year, Kogan faces challenges with negative earnings growth of -73.9% last year and declining profit margins from 1.4% to 0.4%. Its dividend yield of 3.47% isn't well covered by earnings, yet the company trades at a substantial discount to estimated fair value. The seasoned management team averages a tenure of 14.6 years, while short-term assets comfortably cover both short- and long-term liabilities without shareholder dilution in the past year. Click here and access our complete financial health analysis report to understand the dynamics of Learn about future growth trajectory here. Unlock more gems! Our ASX Penny Stocks screener has unearthed 998 more companies for you to here to unveil our expertly curated list of 1,001 ASX Penny Stocks. Want To Explore Some Alternatives? These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ARR ASX:HRN and ASX:KGN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

American Rare Earths Leads ASX Penny Stocks To Consider
American Rare Earths Leads ASX Penny Stocks To Consider

Yahoo

time4 hours ago

  • Yahoo

American Rare Earths Leads ASX Penny Stocks To Consider

As the Australian market experiences a gradual decline, influenced by profit-taking and external geopolitical tensions, investors are seeking opportunities beyond traditional large-cap stocks. Penny stocks, though an older term, continue to attract attention for their potential to offer surprising value and growth at lower price points. By focusing on companies with strong balance sheets and solid fundamentals, investors may uncover hidden gems that provide upside without many of the risks typically associated with this segment of the market. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$70.76M ★★★★★★ GTN (ASX:GTN) A$0.65 A$124.05M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$725.72M ★★★★★☆ Regal Partners (ASX:RPL) A$2.25 A$756.37M ★★★★★★ Accent Group (ASX:AX1) A$1.845 A$1.11B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.37 A$159.91M ★★★★★★ CTI Logistics (ASX:CLX) A$1.815 A$146.19M ★★★★☆☆ Click here to see the full list of 1,001 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: American Rare Earths Limited focuses on the exploration and development of mineral resources in Australia and the United States, with a market cap of A$139.54 million. Operations: American Rare Earths Limited currently does not report any revenue segments. Market Cap: A$139.54M American Rare Earths Limited, with a market cap of A$139.54 million, is pre-revenue and debt-free, focusing on the exploration of mineral resources in Australia and the U.S. Recent developments include significant progress at their Cowboy State Mine in Wyoming, where groundwater monitoring wells have been installed as part of environmental permitting efforts. The company also reported promising assay results from its Halleck Creek project, highlighting elevated rare earth mineralization. Leadership changes have strengthened its executive team with seasoned professionals to advance its U.S.-based strategy for developing a secure critical minerals supply chain. Click here to discover the nuances of American Rare Earths with our detailed analytical financial health report. Learn about American Rare Earths' historical performance here. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Horizon Gold Limited is involved in the exploration, evaluation, development, and production of gold deposits in Australia with a market cap of A$86.90 million. Operations: The company's revenue segment consists of A$0.08 million from exploration activities in Australia. Market Cap: A$86.9M Horizon Gold Limited, with a market cap of A$86.90 million, is pre-revenue and debt-free, focusing on gold exploration in Australia. The company recently reported a small net income for the half-year ended December 31, 2024, marking an improvement from the previous year's loss. Its management team is experienced with an average tenure of 4.5 years and has seen leadership changes to bolster corporate development efforts as it progresses through the Gum Creek Feasibility Study. While its short-term assets cover liabilities, long-term liabilities remain uncovered by current assets. Shareholder dilution has been minimal over the past year. Unlock comprehensive insights into our analysis of Horizon Gold stock in this financial health report. Gain insights into Horizon Gold's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Ltd is an online retailer based in Australia with a market capitalization of A$401.23 million. Operations: The company's revenue is derived from its operations in Australia, with A$309.36 million from Kogan Parent and A$9.96 million from Mighty Ape, as well as in New Zealand, where it generates A$40.02 million from Kogan Parent and A$124.88 million from Mighty Ape. Market Cap: A$401.23M with a market cap of A$401.23 million, is debt-free and has extended its buyback plan duration until May 2026. Despite stable weekly volatility over the past year, Kogan faces challenges with negative earnings growth of -73.9% last year and declining profit margins from 1.4% to 0.4%. Its dividend yield of 3.47% isn't well covered by earnings, yet the company trades at a substantial discount to estimated fair value. The seasoned management team averages a tenure of 14.6 years, while short-term assets comfortably cover both short- and long-term liabilities without shareholder dilution in the past year. Click here and access our complete financial health analysis report to understand the dynamics of Learn about future growth trajectory here. Unlock more gems! Our ASX Penny Stocks screener has unearthed 998 more companies for you to here to unveil our expertly curated list of 1,001 ASX Penny Stocks. Want To Explore Some Alternatives? These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ARR ASX:HRN and ASX:KGN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store